PF 6425090

Drug Profile

PF 6425090

Alternative Names: Clostridium difficile vaccine - Pfizer; PF-06425090; PF-6425090

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Bacterial vaccines; Subunit vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Clostridium infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Clostridium-infections(In volunteers) in Canada (IM, Injection)
  • 29 Mar 2017 Phase-III clinical trials in Clostridium infections (In the elderly, In volunteers, In adults) in USA (IM) (NCT03090191)
  • 01 Feb 2017 Pfizer completes a phase I trial for Clostridium infections (In the elderly, In volunteers) in Japan (IM) (NCT02725437)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top